JOINT FILING AGREEMENTJoint Filing Agreement • September 17th, 2021 • Bracebridge Capital, LLC • Biological products, (no disgnostic substances)
Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree, as of September 17, 2021, that only one statement containing the information required by Schedule 13G, and each amendment thereto, need be filed with respect to the ownership by each of the undersigned of shares of common stock, par value $0.0001 per share, of Clarus Therapeutics Holdings, Inc., and such statement to which this Joint Filing Agreement is attached as Exhibit 99.1 is filed on behalf of each of the undersigned.
